Drug news
NICE rejects Imbruvica (ibrutinib) from Cancer Drugs Fund, as a treatment for mantle cell lymphoma- Janssen Biotech
The National Institute for Health and Care Excellence (NICE) has published draft guidance that rejects from the Cancer Drugs Fund, Imbruvica (ibrutinib) from Janssen Biotech, as a treatment for Mantle Cell Lymphoma (MCL) as its clinical benefits are unclear when compared with current treatments and it is not cost effective. Comments on the guidance are invited by 9 September 2016.
Comment: Ibrutinib was recently recommended by the Scottish Medicines Consortium (SMC) in Scotland for relapsed or refractory MCL.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.